Almirall(0O9B)
EUR --+0.00%
Reward51Moderate
Risk12Low
📊50%Data
Thin 4% profit margin · Revenue growing 11% YoY
0O9B
+0.0 · +0.00%
EUR · LSE
Almirall |
Profitless Growth
Market Cap:1.81Bn
ℹ️
Reward Rating
51
Moderate
Bottom 50% (model universe)
50% data coverage
ℹ️
Risk Rating
12
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0O9B to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Almirall?

operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa.

0O9B · Verdict

Moderate reward · low risk

0O9B stands out on cash flow and volatility, but watch the profitability signal.

Based on 75% data coverage

0O9B · Verdict

What’s working & what to watch

Strengths 3

  • Cash flow95/100

    Top decile vs peers

  • Volatility95/100

    Top decile vs peers

  • Balance sheet88/100

    Current ratio 2.01

Watchouts 1

  • Profitability16/100

    3% return on equity

Model-based scoring. For information only — not financial advice.

What is Almirall?

operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. The company is listed on the LSE in UK, with a market capitalisation of 1.81B.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (51)

The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap1.81B
P/E RatioN/A
Dividend Yield1.84%
52 Week High13.98
52 Week Low9.6351
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding174M
No. of Employees2,108
IndustryN/A
ExchangeLSE
Beta0.191
CurrencyEUR